12 to 20 Plus, Inc. Launching Major National Product Roll-Out Marketing Campaign


SAN LUIS OBISPO, Calif., June 16, 2004 (PRIMEZONE) -- 12 to 20 Plus, Inc. (OTCBB:TTTP) ("The Company") is launching a major national marketing campaign to raise awareness of its brand. "Our recent success in obtaining the necessary capital resources of up to $10 million over the next three years will now allow 12 to 20 Plus (TTTP) to launch its proprietary product lines in the growing $40 billion dietary supplement market with a major marketing effort. It is anticipated within the first stage of our product roll-out we feel the company can accomplish its initial goals by drawing down less than $1,000,000 of our available funds. With proper funding in place we feel confident our national brand promotions will generate immediate revenues," stated an enthused Michael Smith, COO.

Smith explained the strategy: "We are in the initial phase of a major targeted marketing push throughout North America over the next three months."

Capital will be initially be allocated as follows:


 * Marketing campaign
 * Manufacturing and cost of sales
 * Operational expenses
 * New product research, clinical trials on existing products
 * Acquisition costs

Operational expenses will include a modern electronic commerce system that integrates online sales with internal accounting systems providing TTTP with necessary customer relationship management information.

The Company is structured so that it may identify and acquire various existing entities that fit with its corporate concept. It is the intent of management to grow through acquisitions as well as the successful build-out of its marketing plan.

Many companies have been built using this "roll-up" strategy to greatly reduce the time frame and costs for achieving significant revenue streams

The Company has developed a comprehensive marketing strategy that takes into consideration current and upcoming trends in market penetration.

TTTP's strategy is to pursue three principal avenues of distribution:


 * Direct sales through e-commerce. The Company will be using "pay-
   per-click" Internet marketing services based on keywords in
   Internet searches and affiliate programs where our online product
   ads will be viewed on most major Internet sites throughout North
   America, Europe and Asia, reaching 80% of Internet users
   worldwide.

 * Network sales through health care providers such as TTTP's pending
   distribution channel through Banyan Corporation's wholly-owned
   subsidiary, ChiropracticUSA (OTCBB:BANY). 91.4% of 50,000
   chiropractic practices provide retail products to patients
   according to a Chiropractic Economics Magazine study.

 * Utilization of professional sales rep networks to distribute and
   place The Company's products in major food, drug and mass
   merchandising chains such as Walgreen's, Wal-Mart, Longs Drugs,
   Savon, etc.

Initial efforts are now being directed at the domestic market to build a solid consumer base from which TTTP can dramatically and economically expand. Global marketing efforts will be undertaken using established distributors under licensing arrangements.

The Company believes that its marketing approach will require a minimum of advertising support as there is promotion inherent in The Company's e-commerce site and traditional distribution and a web page with related product information disclosures. It is a generally accepted premise, supported by statistics, that consumers will make the healthier decision if they are aware of the alternatives.

About 12 to 20 Plus

12 to 20 Plus, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional formulas and nutraceuticals. One of The Company's flagship products, the Zit Stick(r), is part of a "spa style" acne therapy system. The market for acne remedies is projected to reach $370 million in 2004.

12 to 20 Plus, Inc. also markets highly effective condition-specific dietary supplements through its Nutraceutical Research Group (NRG) division. Retail sales in the dietary supplement market are projected to hit $40 billion by year 2007, according to Frost & Sullivan. These products, manufactured by FDA-approved labs, contain the most sophisticated combination of extensively researched nutritional elements available. Instead of herbs, the Company utilizes potent pharmaceutical grade "amino acids", important protein constituents that serve as neurotransmitter precursors, membrane stabilizers and enzyme precursors. Some of the proprietary NRG products include: Anaplex (tm), an antidepressant drug alternative; VisionKare(tm), an advanced supplement for macular degeneration; ChemoKare(tm), a unique combination of extracts designed to treat the side effects of chemotherapy; QuitSystem(r), a neuronutrient supplementation for recovery from alcohol, drugs and smoking and Hinoki Bana(tm), a treatment for men and women with hair loss problems.

Safe Harbor

The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release (as well as information included in oral statements or other written statements made or to be made by 12 to 20 Plus, Inc.) contains statements that are forward-looking, such as statements relating to the future anticipated direction of the high technology industry, plans for future expansion, various business development activities, planned capital expenditures, future funding sources, anticipated sales growth and potential contracts. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by or on behalf of 12 to 20 Plus, Inc. These risks and uncertainties include, but are not limited to, those relating to development and expansion activities, dependence on existing management, financing activities, domestic and global economic conditions, changes in federal or state tax laws, and market competition factors. For a description of additional risks and uncertainties, please refer to 12 to 20 Plus filings with the Securities and Exchange Commission.


            

Kontaktdaten